Decreased TET2 gene expression during chronic myeloid leukemia progression

Leuk Res. 2011 Nov;35(11):e220-2. doi: 10.1016/j.leukres.2011.07.013. Epub 2011 Jul 27.

Abstract

Recently it has been demonstrated that ten-eleven-translocation-2 (TET2) gene alterations may represent a crucial event in the pathogenesis of various myeloid malignancies. To date, the loss of TET2 function has been solely ascribed to mutations in the gene coding region. In this study, we report a chronic myeloid leukemia (CML) case showing a TET2 single copy partial deletion associated to a t(4;6;11) rearrangement, appearing during the progression of the disease and responsible for a decreased TET2 gene expression. A putative role for TET2 haploinsufficiency in this patient's CML progression is discussed.

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chromosomes, Human, Pair 11 / genetics*
  • Chromosomes, Human, Pair 4 / genetics*
  • Chromosomes, Human, Pair 6 / genetics*
  • DNA, Neoplasm / genetics
  • DNA-Binding Proteins / genetics*
  • Dioxygenases
  • Disease Progression
  • Follow-Up Studies
  • Fusion Proteins, bcr-abl / genetics
  • Gene Deletion*
  • Gene Rearrangement
  • Humans
  • In Situ Hybridization, Fluorescence
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Male
  • Middle Aged
  • Proto-Oncogene Proteins / genetics*
  • Real-Time Polymerase Chain Reaction

Substances

  • DNA, Neoplasm
  • DNA-Binding Proteins
  • Proto-Oncogene Proteins
  • Dioxygenases
  • TET2 protein, human
  • Fusion Proteins, bcr-abl